Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 184,915 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Terminated Phase 1 Interventional

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

NCT04396340
View directory record Official record
Conditions
Ovarian Cancer, Nonsmall Cell Lung Cancer
Interventions
XMT-1592
Biological
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

NCT03266640
View directory record Official record
Conditions
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Interventions
viral specific cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

NCT00374140
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
RAD001 (everolimus)
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
19
States / cities
Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

NCT07842640
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Early Phase 1 Interventional Results available

New Tool to Enhance Post-stroke Upper Extremity Disability

NCT05277389
View directory record Official record
Conditions
Stroke
Interventions
START - Startle Adjuvant Rehabilitation Therapy, Sham Control
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 31, 2026, 3:19 AM EDT
Not listed Phase 4 Interventional

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring

NCT02479789
View directory record Official record
Conditions
Thyroidectomy, Nerve Monitoring
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Bronx-Lebanon Hospital Center Health Care System
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 31, 2026, 3:19 AM EDT
Not listed Phase 1Phase 2 Interventional

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

NCT05498389
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors
Interventions
EMB-01, Osimertinib
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

NCT01849289
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Phase 1 Interventional

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT07487168
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multisite Observational Maternal and Infant Study for COVID-19

NCT05031468
View directory record Official record
Conditions
COVID-19
Interventions
Licensed or EUA SARS-CoV-2 vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 31, 2026, 3:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268
View directory record Official record
Conditions
NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Interventions
Oral MRT-2359
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

RegoNivo vs Standard of Care Chemotherapy in AGOC

NCT04879368
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Drug · Biological
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Not applicable Interventional Results available

Modafinil, Sleep, and Cognition in Cocaine Dependence

NCT00582491
View directory record Official record
Conditions
Cocaine Dependence, Substance-induced Sleep Disorder, Substance-induced Cognitive Disorder
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

NCT06728774
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Cognitive Dysfunction
Interventions
Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD), Goal-focused Supportive Contact
Behavioral
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum

NCT01327274
View directory record Official record
Conditions
Pectus Excavatum
Interventions
Magnetic Mini-Mover Procedure (Magnimplant)
Device
Lead sponsor
Michael Harrison
Other
Eligibility
8 Years to 14 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 1 Interventional

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

NCT00877474
View directory record Official record
Conditions
ADVANCED SOLID TUMORS
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Results available

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

NCT02593318
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

NCT00096018
View directory record Official record
Conditions
Leukemia
Interventions
fludarabine phosphate, thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY4065967, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia

NCT05317390
View directory record Official record
Conditions
Dystonia, Drug Induced Dystonia, Parkinson Disease, Essential Tremor, Dyskinesias, Myoclonus, Tic Disorders, Torticollis, Ulnar Nerve Entrapment, Temporomandibular Joint Disorders, Dysphonia
Interventions
DystoniaNet-based diagnosis of isolated dystonia
Diagnostic Test
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 4 Interventional

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

NCT00168090
View directory record Official record
Conditions
Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
Interventions
Blood coagulation Factor VIII and vWF, human
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Not applicable Interventional

Respiratory Effects of E-Cigarettes in Obese Youth

NCT05869318
View directory record Official record
Conditions
E-Cig Use
Interventions
ECIG own, ECIG Vuse
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 31, 2026, 3:19 AM EDT